Fox Run Management’s Nektar Therapeutics NKTR Stock Holding History

Fox Run Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$448K	Sell	6,871 -19,651	-74%	-$1.12M	0.08%	488
2025 Q4	$1.12M	Buy	+26,522	New	+$1.48M	0.17%	163
2022 Q1	–	Sell	-926	Closed	-$188K	–	635
2021 Q4	$188K	Buy	+926	New	+$201K	0.11%	375
2020 Q1	–	Sell	-1,056	Closed	-$342K	–	286
2019 Q4	$342K	Buy	+1,056	New	+$306K	0.28%	134
2019 Q1	–	Sell	-778	Closed	-$384K	–	622
2018 Q4	$384K	Buy	+778	New	+$470K	0.2%	191
2018 Q3	–	Sell	-345	Closed	-$253K	–	741
2018 Q2	$253K	Buy	345 +214	+163%	+$247K	0.08%	498
2018 Q1	$209K	Buy	+131	New	+$169K	0.05%	618

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fox Run Management's NKTR Position: Q1 2026 in Review

Fox Run Management reduced its Nektar Therapeutics (NKTR) stake by 74% in Q1 2026, selling an estimated $1.12M and leaving 6,871 shares worth $448K. The position accounts for 0.08% of the portfolio, ranked #488.

Fox Run Management first reported a position in NKTR in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.12M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Fox Run Management held 6,871 shares of Nektar Therapeutics worth $448K as of Q1 2026.
Fox Run Management sold 19,651 Nektar Therapeutics shares in Q1 2026, an estimated $1.12M.
Nektar Therapeutics made up 0.08% of Fox Run Management's portfolio in Q1 2026, its #488 holding.
Fox Run Management first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 7 quarters since.
Fox Run Management's Nektar Therapeutics position peaked at $1.12M in Q4 2025.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.